KCI NPWT solution shows benefits in newly-published resource

KCI has announced the publication of a report showing the benefits of its negative pressure wound therapy (NPWT) offering VAC VeraFlo Instillation Therapy.

The supplement, published in the International Wound Journal, outlines current wound care challenges and practices, presenting clinical evidence related to the use of this approach to cleansing and treating contaminated or complex wounds.

Based on presentations from the 2012 and 2013 International Surgical Wound Forum, it covers topics such as surgical site infections, instillation in diabetic foot wounds and instillation with various topical solutions.

More than a dozen recognised wound care leaders have contributed to the new supplement, which will prove a useful resource in the treatment of acute and chronic wounds.

Dr Ron Silverman, chief medical officer at KCI, said: "This dedicated supplement significantly adds to the growing body of evidence and guidelines supporting VAC VeraFlo Therapy and further illustrates how VAC VeraFlo Therapy is changing clinicians' approach to treating wounds."

Recent studies have shown that VAC VeraFlo offers a number of benefits compared to traditional VAC negative-pressure wound therapy, including reductions in the key metrics of hospital length of stay, time to wound closure and debridement cost.